Emergent Biosolutions Stock Analysis
EBS Stock | USD 9.40 0.52 5.86% |
Emergent Biosolutions is overvalued with Real Value of 7.71 and Target Price of 6.0. The main objective of Emergent Biosolutions stock analysis is to determine its intrinsic value, which is an estimate of what Emergent Biosolutions is worth, separate from its market price. There are two main types of Emergent Biosolutions' stock analysis: fundamental analysis and technical analysis.
The Emergent Biosolutions stock is traded in the USA on New York Stock Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Emergent Biosolutions is usually not traded on Memorial Day, Juneteenth Holiday, Independence Day, Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday. Emergent Stock trading window is adjusted to America/New York timezone.
Emergent |
Emergent Stock Analysis Notes
About 58.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.95. Some equities with similar Price to Book (P/B) outperform the market in the long run. Emergent Biosolutions has Price/Earnings To Growth (PEG) ratio of 1.55. The entity recorded a loss per share of 11.22. The firm had not issued any dividends in recent years. Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats in the United States. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Emergent Biosolutions operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on New York Stock Exchange. It employs 2416 people. To learn more about Emergent Biosolutions call Joseph Papa at 240 631 3200 or check out https://www.emergentbiosolutions.com.Emergent Biosolutions Quarterly Total Revenue |
|
Emergent Biosolutions Investment Alerts
Emergent Biosolutions had very high historical volatility over the last 90 days | |
The company reported the last year's revenue of 1.05 B. Reported Net Loss for the year was (760.5 M) with profit before taxes, overhead, and interest of 290.1 M. | |
Emergent Biosolutions has about 642.6 M in cash with (206.3 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.28. | |
Roughly 58.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from finance.yahoo.com: Emergent, LLC Wins A Red Hat 2024 North America Public Sector Pinnacle Award |
Emergent Biosolutions Upcoming and Recent Events
26th of February 2024 Upcoming Quarterly Report | View | |
14th of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
26th of February 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Emergent Largest EPS Surprises
Earnings surprises can significantly impact Emergent Biosolutions' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2009-11-05 | 2009-09-30 | 0.06 | 0.03 | -0.03 | 50 | ||
2009-03-05 | 2008-12-31 | 0.02 | 0.05 | 0.03 | 150 | ||
2008-05-07 | 2008-03-31 | 0.27 | 0.24 | -0.03 | 11 |
Emergent Biosolutions Environmental, Social, and Governance (ESG) Scores
Emergent Biosolutions' ESG score is a quantitative measure that evaluates Emergent Biosolutions' performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of Emergent Biosolutions' operations that may have significant financial implications and affect Emergent Biosolutions' stock price as well as guide investors towards more socially responsible investments.
Emergent Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares | Dimensional Fund Advisors, Inc. | 2024-09-30 | 659.3 K | Jpmorgan Chase & Co | 2024-06-30 | 649.5 K | Goldman Sachs Group Inc | 2024-06-30 | 611 K | Two Sigma Advisers, Llc | 2024-06-30 | 575.4 K | Geode Capital Management, Llc | 2024-06-30 | 556.2 K | Bank Of America Corp | 2024-06-30 | 554.9 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 542.8 K | Renaissance Technologies Corp | 2024-09-30 | 524.9 K | Jane Street Group Llc | 2024-06-30 | 490.8 K | Blackrock Inc | 2024-06-30 | 3.8 M | Vanguard Group Inc | 2024-09-30 | 3.4 M |
Emergent Market Capitalization
The company currently falls under 'Small-Cap' category with a total capitalization of 540.22 M.Emergent Profitablity
The company has Net Profit Margin of (0.19) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of 0.25 %, which entails that for every 100 dollars of revenue, it generated $0.25 of operating income.Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.61) | (0.57) | |
Return On Capital Employed | (0.62) | (0.59) | |
Return On Assets | (0.42) | (0.40) | |
Return On Equity | (1.17) | (1.11) |
Management Efficiency
Emergent Biosolutions has Return on Asset of (0.0422) % which means that on every $100 spent on assets, it lost $0.0422. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.3464) %, meaning that it generated no profit with money invested by stockholders. Emergent Biosolutions' management efficiency ratios could be used to measure how well Emergent Biosolutions manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to gain to -0.57 in 2024. Return On Capital Employed is likely to gain to -0.59 in 2024. At this time, Emergent Biosolutions' Non Currrent Assets Other are comparatively stable compared to the past year. Other Assets is likely to gain to about 231 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 799.2 M in 2024.Last Reported | Projected for Next Year | ||
Book Value Per Share | 12.68 | 10.41 | |
Tangible Book Value Per Share | 1.62 | 1.53 | |
Enterprise Value Over EBITDA | (1.72) | (1.64) | |
Price Book Value Ratio | 0.19 | 0.18 | |
Enterprise Value Multiple | (1.72) | (1.64) | |
Price Fair Value | 0.19 | 0.18 | |
Enterprise Value | 1.6 B | 1.7 B |
Emergent Biosolutions' management has consistently demonstrated strong leadership, driving both financial growth and operational excellence. By analyzing current market trends and future growth opportunities, we assess the stock's true value and potential for investors.
Operating Margin 0.2451 | Profit Margin (0.19) | Beta 1.574 | Return On Assets (0.04) | Return On Equity (0.35) |
Technical Drivers
As of the 22nd of November, Emergent Biosolutions shows the Coefficient Of Variation of 15013.36, mean deviation of 4.74, and Downside Deviation of 6.43. Emergent Biosolutions technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Emergent Biosolutions variance, as well as the relationship between the value at risk and skewness to decide if Emergent Biosolutions is priced favorably, providing market reflects its regular price of 9.4 per share. Given that Emergent Biosolutions has jensen alpha of (0.23), we urge you to verify Emergent Biosolutions's prevailing market performance to make sure the company can sustain itself at a future point.Emergent Biosolutions Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Emergent Biosolutions middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Emergent Biosolutions. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Emergent Biosolutions Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Emergent Biosolutions insiders, such as employees or executives, is commonly permitted as long as it does not rely on Emergent Biosolutions' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Emergent Biosolutions insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Emergent Biosolutions Outstanding Bonds
Emergent Biosolutions issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Emergent Biosolutions uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Emergent bonds can be classified according to their maturity, which is the date when Emergent Biosolutions has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Boeing Co 2196 Corp BondUS097023DG73 | View | |
HSBC Holdings PLC Corp BondUS404280DR76 | View | |
EMBRAER NETH FIN Corp BondUS29082HAB87 | View | |
EMERGENT BIOSOLUTIONS INC Corp BondUS29089QAC96 | View | |
US29082KAA34 Corp BondUS29082KAA34 | View | |
MGM Resorts International Corp BondUS552953CD18 | View | |
EMERA INC 675 Corp BondUS290876AD37 | View |
Emergent Biosolutions Predictive Daily Indicators
Emergent Biosolutions intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Emergent Biosolutions stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Emergent Biosolutions Corporate Filings
F3 | 21st of November 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
F4 | 14th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 13th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
S1 | 12th of November 2024 Report filed by companies planning on going public to register their securities with the U.S. Securities and Exchange Commission (SEC) | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 7th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 17th of October 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Emergent Biosolutions Forecast Models
Emergent Biosolutions' time-series forecasting models are one of many Emergent Biosolutions' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Emergent Biosolutions' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Emergent Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Emergent Biosolutions prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Emergent shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Emergent Biosolutions. By using and applying Emergent Stock analysis, traders can create a robust methodology for identifying Emergent entry and exit points for their positions.
Last Reported | Projected for Next Year | ||
Pretax Profit Margin | (0.70) | (0.66) | |
Operating Profit Margin | (0.69) | (0.66) | |
Net Loss | (0.72) | (0.69) | |
Gross Profit Margin | 0.33 | 0.23 |
Current Emergent Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Emergent analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Emergent analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target Price | Advice | # of Analysts | |
6.0 | Buy | 2 | Odds |
Most Emergent analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Emergent stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Emergent Biosolutions, talking to its executives and customers, or listening to Emergent conference calls.
Emergent Stock Analysis Indicators
Emergent Biosolutions stock analysis indicators help investors evaluate how Emergent Biosolutions stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Emergent Biosolutions shares will generate the highest return on investment. By understating and applying Emergent Biosolutions stock analysis, traders can identify Emergent Biosolutions position entry and exit signals to maximize returns.
Begin Period Cash Flow | 642.6 M | |
Long Term Debt | 446.5 M | |
Common Stock Shares Outstanding | 51.2 M | |
Total Stockholder Equity | 649.3 M | |
Tax Provision | 49.4 M | |
Quarterly Earnings Growth Y O Y | 0.022 | |
Property Plant And Equipment Net | 399 M | |
Cash And Short Term Investments | 111.7 M | |
Cash | 111.7 M | |
Accounts Payable | 112.2 M | |
Net Debt | 748.5 M | |
50 Day M A | 8.6254 | |
Total Current Liabilities | 651.3 M | |
Other Operating Expenses | 1.7 B | |
Non Current Assets Total | 1.1 B | |
Forward Price Earnings | 7.9428 | |
Non Currrent Assets Other | 178.1 M | |
Stock Based Compensation | 23.1 M |
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.